Pancreatic Cancer Research

ResearcherGeorge Mason UniversityActive in the last 2 years

Emanuel F. Petricoin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8787-5990; OpenAlex author ID A5111627994, A5115076571. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
50
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 5 papers · 2026: 1 paper

Papers 8

  1. A KRT17/GATA6 hybrid state marks unique vulnerability to MYC in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-11519779/v1↗
  2. Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database. Co-author DOI 10.1093/oncolo/oyaf007↗
  3. Defining the MYC-regulated transcriptome and kinome that support KRAS- and ERK-dependent growth of pancreatic cancer. Co-author DOI 10.1126/scisignal.adu7145↗
  4. Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-1757↗
  5. Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Ca… Co-author DOI 10.1158/0008-5472.can-25-1507↗
  6. HuR-Regulated Extracellular Vesicles Promote Endothelial Cell Remodeling in Pancreatic Cancer. Co-author DOI 10.1158/2767-9764.crc-25-0355↗
  7. Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-0391↗
  8. Proteomic analysis reveals Warburg effect and anomalous metabolism of glutamine in pancreatic cancer cells. Last author DOI 10.1021/pr2009274↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kristina Drizyte‐Miller · 4 shared papers, 2023–2025 · strength 0.69
  2. Kirsten L. Bryant · 4 shared papers, 2023–2025 · strength 0.69
  3. Adrienne D. Cox · 4 shared papers, 2023–2025 · strength 0.69
  4. Clint A. Stalnecker · 4 shared papers, 2023–2025 · strength 0.69
  5. Channing J. Der · 4 shared papers, 2023–2025 · strength 0.69
  6. Mariaelena Pierobon · 3 shared papers, 2023–2025 · strength 0.50
  7. Ryan N. Robb · 2 shared papers, 2025 · strength 0.37
  8. Mallory K. Roach · 2 shared papers, 2025 · strength 0.37
  9. Jennifer E. Klomp · 2 shared papers, 2023–2025 · strength 0.32
  10. Andrew M. Waters · 2 shared papers, 2023–2025 · strength 0.32
  11. Jennifer M. Finan · 1 shared paper, 2025 · strength 0.22
  12. Yifei Guo · 1 shared paper, 2025 · strength 0.22
  13. Kevin Hawthorne · 1 shared paper, 2025 · strength 0.22
  14. Margaret E. Haerr · 1 shared paper, 2025 · strength 0.22
  15. Zheng Xia · 1 shared paper, 2025 · strength 0.22
  16. Canping Chen · 1 shared paper, 2025 · strength 0.22
  17. Rosalie C. Sears · 1 shared paper, 2025 · strength 0.22
  18. Jonathan Robert Brody · 1 shared paper, 2025 · strength 0.22
  19. Katelyn T. Byrne · 1 shared paper, 2025 · strength 0.22
  20. Lyanne Delgado Coka · 1 shared paper, 2026 · strength 0.21
  21. Luisa F. Escobar‐Hoyos · 1 shared paper, 2026 · strength 0.21
  22. Kenneth Reed Shroyer · 1 shared paper, 2026 · strength 0.21
  23. Scott Powers · 1 shared paper, 2026 · strength 0.21
  24. Rachna T. Shroff · 1 shared paper, 2025 · strength 0.20
  25. Matthew Ebia · 1 shared paper, 2025 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.